1. Home
  2. GITS vs IMRN Comparison

GITS vs IMRN Comparison

Compare GITS & IMRN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

GITS

Global Interactive Technologies Inc.

HOLD

Current Price

$2.64

Market Cap

7.6M

Sector

N/A

ML Signal

HOLD

Logo Immuron Limited

IMRN

Immuron Limited

N/A

Current Price

$0.72

Market Cap

6.8M

Sector

Health Care

ML Signal

N/A

Company Overview

Basic Information
Metric
GITS
IMRN
Founded
2018
1994
Country
South Korea
Australia
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Sector
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
7.6M
6.8M
IPO Year
N/A
2016

Fundamental Metrics

Financial Performance
Metric
GITS
IMRN
Price
$2.64
$0.72
Analyst Decision
Analyst Count
0
0
Target Price
N/A
N/A
AVG Volume (30 Days)
110.3K
21.1K
Earning Date
11-12-2025
02-25-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$0.66
$0.68
52 Week High
$7.09
$2.38

Technical Indicators

Market Signals
Indicator
GITS
IMRN
Relative Strength Index (RSI) 51.00 39.20
Support Level $2.13 $0.69
Resistance Level $3.03 $0.89
Average True Range (ATR) 0.37 0.06
MACD -0.00 -0.01
Stochastic Oscillator 56.96 0.05

Price Performance

Historical Comparison
GITS
IMRN

About GITS Global Interactive Technologies Inc.

Global Interactive Technologies Inc, formerly Hanryu Holdings Inc is the creator of the engaging social media platform, FANTOO. Through FANTOO, it provides a multi-media platform for its users to interact with other like-minded users, share their appreciation of various types of entertainment and cultures, create their content, enjoy content, and engage in commerce.

About IMRN Immuron Limited

Immuron Ltd is a commercial and clinical-stage biopharmaceutical company with a proprietary technology platform focused on polyclonal antibodies that can address unmet medical needs. The company's commercial products are: Travelan (an orally administered passive product indicated to reduce the risk of travelers' diarrhea and minor gastrointestinal disorders), and Protectyn, which is marketed as an immune supplement. Additionally, it has two clinical products in development, IMM124-E and IMM529, for the treatment of multiple high-value enteric disease indications. The firm has two reportable segments: Hyper-immune products, which derive maximum revenue, and Research and development. Geographically, the company generates maximum revenue from Australia, followed by the USA and Canada.

Share on Social Networks: